CJC-1295 (With DAC)

Long-acting GHRH analogue for sustained GH elevation models.

CJC-1295 with Drug Affinity Complex features a lysine-maleimidopropionic acid modification enabling covalent albumin binding, extending half-life to 6–8 days. This sustained-release profile creates a prolonged GH elevation rather than pulsatile release, making it relevant to research models studying continuous GH effects, IGF-1 amplification, and metabolic outcomes.

Research Applications

• Albumin-binding DAC modification
• 6–8 day half-life profile
• Sustained IGF-1 elevation
• Metabolic effects of continuous GH
• Long-interval dosing protocols